Olema Pharmaceuticals
OLMA
97 hedge funds and large institutions have $359M invested in Olema Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 33 increasing their positions, 13 reducing their positions, and 19 closing their positions.
408% more call options, than puts
Call options by funds: $1.16M | Put options by funds: $229K
154% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 13
116% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 19
28% more funds holding
Funds holding: 76 → 97 (+21)
2.5% more ownership
Funds ownership: 92.88% → 95.38% (+2.5%)
65% less capital invested
Capital invested by funds: $1.01B → $359M (-$653M)
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$15.5M |
| 2 |
Two Sigma Advisers
New York
|
+$11.6M |
| 3 |
Two Sigma Investments
New York
|
+$10.9M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$10.8M |
| 5 |
Morgan Stanley
New York
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$22.3M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$18.7M |
| 3 |
VA
VR Adviser
New York
|
-$14.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$12.3M |
| 5 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$9.43M |
OLMA Hedge Fund Activity: Q4 2021 in Review
97 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q4 2021, worth a combined $359M — down 65% from $1.01B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new OLMA positions and 19 closed out — a net gain of 22 holders — while 33 added to existing stakes and 13 trimmed.
The largest buyer was BVF Inc, adding an estimated $15.5M. The largest seller was OrbiMed, exiting entirely with an estimated $22.3M sold.
- 97 institutional investors held Olema Pharmaceuticals (OLMA) as of Q4 2021, up from 76 in Q3 2021.
- Funds reported $359M of Olema Pharmaceuticals stock for Q4 2021, down 65% quarter-over-quarter.
- 41 funds opened new Olema Pharmaceuticals positions in Q4 2021 and 19 closed out, a net change of +22 holders.
- The largest Olema Pharmaceuticals buyer in Q4 2021 was BVF Inc, an estimated $15.5M added.
- The largest Olema Pharmaceuticals seller in Q4 2021 was OrbiMed, an estimated $22.3M sold.
Based on aggregated 13F filings for Q4 2021.